kabutan

Modalis Therapeutics Corporation(4883) Summary

4883
TSE Growth
Modalis Therapeutics Corporation
59
JPY
-1
(-1.67%)
Jan 29, 3:30 pm JST
0.38
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
59.6
Jan 29, 8:55 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.92
Yield
ー%
Margin Trading Ratio
5,129.87
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
60 JPY 0.39 USD
Previous Close Jan 28
60 JPY 0.39 USD
High Jan 29, 9:00 am
60 JPY 0.39 USD
Low Jan 29, 9:11 am
59 JPY 0.38 USD
Volume
263,000
Trading Value
0.02B JPY 0.10M USD
VWAP
59.63 JPY 0.39 USD
Minimum Trading Value
5,900 JPY 38 USD
Market Cap
5.11B JPY 0.03B USD
Number of Trades
83
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
417
1-Year High Jun 9, 2025
9,562
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 9,670,900
Jan 16, 2026 0 9,452,100
Jan 9, 2026 0 9,368,100
Dec 26, 2025 0 9,722,200
Dec 19, 2025 0 9,955,300
Company Profile
Modalis Therapeutics Corporation conducts research and development of gene therapy drugs using its proprietary genome editing platform. The company has a base in the United States.
Sector
Pharmaceuticals
Modalis Therapeutics Corporation utilizes its proprietary genome editing platform, centered on CRISPR-GNDM technology, to research and develop gene therapy drugs. This technology functions as a "gene switch" that can control gene expression without cutting DNA, offering higher safety compared to conventional genome editing methods. The company aims to address genetic diseases, which are often in the rare disease category and inefficient to develop using traditional drug discovery approaches, by leveraging its technological prowess. Modalis employs a hybrid business model, combining partnerships with pharmaceutical companies ("collaboration model") and in-house development ("proprietary model"). The collaboration model aims for early revenue generation, while the proprietary model targets larger future revenues. The company has several ongoing development pipelines and aims to secure licensing agreements at specific stages of development.